• Policy
• Will SGLT2 combi benefit expansion eventually not happen?
• by Lee, Tak-Sun Dec 12, 2022 05:48am

• Policy
• “Yoon admin’s healthcare policy reduces coverage"
• by Kim, Jung-Ju Dec 9, 2022 06:03am

• Policy
• Dong-A launches its first generic Dapapro
• by Lee, Tak-Sun Dec 8, 2022 06:05am

• Policy
• Only K-CAB continues to be applied refund-type PVA
• by Lee, Tak-Sun Dec 7, 2022 05:55am

• Policy
• Vaccine sales reached 3.4178 trillion won in Korea last year
• by Lee, Hye-Kyung Dec 7, 2022 05:55am

• Policy
• Reimb of antidiabetic SGLT-2+DPP-4 combo near
• by Kim, Jung-Ju Dec 7, 2022 05:55am

• Policy
• One-shot Zolgensma fulfills terms of its RSA contract
• by Kim, Jung-Ju Dec 6, 2022 05:57am

• Policy
• The government is conducting six studies on drug prices
• by Kim, Jung-Ju Dec 6, 2022 05:57am

• Policy
• "A9 countries not used for drug pricing reevals next year"
• by Kim, Jung-Ju Dec 5, 2022 05:53am

• Policy
• Implementation of projects linked to permission evaluation
• by Kim, Jung-Ju Dec 5, 2022 05:53am